AzTrials
AzTrials

Muscle HypotrophyNCT05573321

The Effect of Blood Flow Restriction (Bfr) Exercise on Acute Systemic Myokine Levels in Healthy Trained Men

A study testing BFR-RE and HL-RE in people with Muscle Hypotrophy, run by Ege University.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The aim of the study is to measure and compare acute systemic irisin, myostatin and decorin levels after a single session of blood flow restricted resistance exercise and resistance exercise without blood flow restriction in healthy, trained male participants aged 18-35 years. Read more about this study

Who is it for?
Ages 18 to 35 years, men onlyHealthy volunteers can take part
Conditions the study is for
Muscle Hypotrophy
What is being tested?
BFR-RE and HL-RE
Could I receive a placebo?
No, everyone receives an active treatment
How many people
22 participants
Where
No sites listed yet
Study dates
14 Feb 2023to Jun 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 35 years
  • Men only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Being between 18-35 years old and male gender
  • To have been doing resistance exercises for at least 1 year and to be accustomed to lower extremity resistance exercises
  • Not doing any resistance exercise with restricted blood flow in the last 1 month
  • Not doing lower extremity resistance exercise for at least 48 hours
  • Answering no to all questions in the Exercise Readiness Questionnaire (EGZ-A+)

Who cannot join

  • Presence of musculoskeletal injury or disability that may prevent exercise with restricted blood flow
  • Using non-steroidal anti-inflammatory drugs (NSAIDs) or supplements that may have an anti-inflammatory effect
  • Being at risk for cardiovascular disease
  • Regular use of tobacco products
  • Using ergogenic support

Trial locations and contacts

No sites are listed yet.

About this study

Official title: Effect of Blood Flow Restriction Exercise on Acute Systemic Irisin, Myostatin and Decorin Levels

The aim of the study is to measure and compare acute systemic irisin, myostatin and decorin levels after a single session of blood flow restricted resistance exercise and resistance exercise without blood flow restriction in healthy, trained male participants aged 18-35 years. For this purpose, a total of 22 people will be included in the study. Participants will be randomly allocated to 2 exercise groups as resistance exercise with blood flow restriction (BFR-RE) and resistance exercise without blood flow restriction (HL-RE) and will be subjected to cross-over. In the HL-RE intervention, the exercise will be performed with a loading of 80% of 1 RM, with 4 sets x 7 repetitions, with 60 seconds of rest between sets. In the BFR-RE intervention, the exercise will be done as a set of 30 repetitions with a loading of 30% of 1 RM and an additional 3 sets x 15 repetitions, with 30 seconds rest between sets. Total exercise volumes were tried to be equalized and skeletal muscle hypertrophy was selected in accordance with exercise guidelines. In both groups, bilateral leg extension exercise will be performed using the leg extension machine for resistance exercise. In the blood flow restriction group (BFR-RE), the cuff will be placed in the proximal region of the thigh bilaterally, inflated to a pressure equivalent to 50% of the estimated arterial occlusion pressure (AOP), and leg extension exercise will be performed under this condition. In the BFR-RE group, the blood flow restriction time will be between 5-10 minutes. Exercise sessions will be conducted under supervision. Venous blood samples will be collected from the arm antecubital region of the participants just before the exercise session, immediately after the exercise, and 1 hour after the exercise. Plasma irisin, myostatin and decorin levels will be measured from the samples taken. It is well known that resistance exercise is important in maintaining and increasing muscle mass (hypertrophy). Studies have shown the involvement of certain myokines in skeletal muscle hypertrophy, although few studies have been conducted on the systemic response of myokines to BFR-RE that may play a potential role in hypertrophy. Therefore, the planned study aimed to reveal the similarities or differences in the systemic myokine response between BFR-RE and HL-RE.

Read the detailed description

Resistance exercise is a type of exercise classically used to increase skeletal muscle hypertrophy and muscle strength. Resistance training is an important component of training in most sports, and it also plays a role in injury prevention and rehabilitation. In dynamic resistance exercise, the intensity is usually determined by measuring the maximum weight that can be lifted only once (one repetition maximum, 1RM). The American College of Sports Medicine (ACSM) recommends more than 70% of 1RM to increase muscle mass (high load resistance exercise, HL-RE). High-intensity loads recommended by the ACSM may not be a suitable option for populations with sarcopenia, the elderly with chronic health conditions, or those with injuries that cannot tolerate heavy load, as they create excessive mechanical stress on the tissues during exercise and pose a potential risk of injury. There is increasing evidence that the use of blood flow restriction (BFR), also known as occlusion or Kaatsu training, with low-load resistance exercise (<50% 1RM) provides hypertrophic gains. This training method (BFR RE) is an exercise method performed by placing an inflatable cuff on the proximal part of the extremity (arm or leg) to restrict blood flow and restricting venous return distal to the obstruction without obstructing arterial flow. As publications using this method increase, interest in BFR-RE has increased to increase skeletal muscle hypertrophy and strength in athletes, the elderly, or clinical populations (such as cerebrovascular, cardiac, neuromuscular diseases, obesity). Standard hypertrophy exercise parameters consist of 1-3 total sets, 8-12 repetitions for sets, and 1-2 minutes rest between sets, with a loading of 70-85% of 1RM in beginner-intermediate levels. BFR-RE, on the other hand, consists of a loading interval of 20-40% of 1RM, a set of 30 repetitions, followed by 3 additional sets of 15 repetitions, with 30 seconds of rest between sets. Despite this difference in exercise protocols, both approaches provide skeletal muscle hypertrophy. Studies show that low-load-high-rep resistance exercises, when performed until fatigue, cause skeletal muscle hypertrophy similar to high-load-low-rep resistance exercises. In addition, BFR-RE is superior to unrestricted low-load resistance exercise in terms of skeletal muscle hypertrophy when the exercise volume is equalized. According to a meta-analysis, BFR-RE has been shown to induce increases in muscle mass comparable to HL-RE regardless of absolute occlusion pressure, cuff width, and method of generating occlusion pressure. Although the potent hypertrophic effects of BFR-RE have been demonstrated by numerous studies, the underlying mechanisms responsible for such effects are not well defined. Although the potent hypertrophic effects of BFR-RE have been demonstrated by numerous studies, the underlying mechanisms responsible for such effects are not well defined. Metabolic stress (accumulation of metabolites as a result of the ischemic/hypoxic environment) has been suggested to be the primary responsible factor, and is thought to activate numerous other mechanisms thought to induce muscle hypertrophy through autocrine and/or paracrine actions. Secondary mechanisms activated by metabolic stress include involvement of fast twitch muscle fibers (type 2 fibers), release of certain hormones (GH, IGF-1), myokine production, production of reactive oxygen products and cell swelling. However, it is important to recognize that some of these mechanisms are largely induced not by metabolic stress but rather by mechanical tension (another primary factor of muscle hypertrophy). Given that mechanical strain is typically low (<50% 1RM) in BFR-RE, the extent of its involvement in hypertrophic adaptations is questionable. However, mechanical tension and metabolic stress, which are ultimately the primary factors responsible for hypertrophy, act synergistically to produce muscle hypertrophy in BFR-RE. Cytokines are a large family of polypeptides and proteins that function as intercellular messengers. While their primary function is typically associated with immune response, many cytokines appear to exhibit functional pleiotropy. A cytokine may mediate different effects depending on the initial stimulus, the target cell, or other co-released cytokines. Cytokines can also act locally (autocrine or paracrine) or systemically (endocrine) depending on the target tissue. Skeletal muscle has been found to release cytokines in response to muscle contraction. These cytokines, called myokines, have local effects on muscle as well as systemic effects on other tissues. Myokine release after muscle contraction varies according to the intensity, mode and volume of the exercise performed by the person. There are theories that metabolic stress may mediate muscle hypertrophy by upregulating anabolic myokines and/or downregulating catabolic myokines. Irisin was discovered by Bostrom et al in 2012 as a PGC-1α (peroxisome proliferator-activated receptor coactivator 1-alpha)-dependent myokine. It is proteolytically cleaved from the membrane protein FDNC-5 (fibronectin domain-containing protein-5) and secreted from skeletal muscle into the circulation in response to exercise. Irisin is a myokine primarily known for its effect on the conversion of white adipose tissue to brown adipose tissue, thereby increasing thermogenesis and energy metabolism. However, there is new evidence suggesting that the iris may have a role in regulating muscle hypertrophy. Recent studies show that acute intense resistance exercise increases circulating irisin concentrations. It has been reported that irisin induces skeletal muscle hypertrophy and reduces denervation-induced atrophy by activating IL-6 in rodents. It also suggests that irisin may play a role in skeletal muscle hypertrophy by upregulating IGF-1 and downregulating myostatin in human myocyte cultures and in vitro treatment with irisin. Myostatin is a member of the TGF-ß (transforming growth factor-beta) family and acts as a negative regulator of skeletal muscle development. High myostatin levels are significantly associated with muscle wasting diseases, myopathy and sarcopenia. A significant increase in muscle mass was observed in individuals with mutations in both copies of the myostatin gene compared to normal individuals. There are studies showing that myostatin level decreases with a single session of resistance exercise. It has been shown that myostatin levels in the plantaris muscle of rats following blood flow restricted exercise (BFR) were significantly reduced compared to the sham group. Decorin has been defined as another myokine that plays a role in muscle hypertrophy. Myotubes secrete decorin and decorin regulates protein synthesis in vitro. In addition, in vivo evidence from rodent skeletal muscle has shown that overexpression of decorin can upregulate several factors involved in inhibiting myostatin, a potent myokine that decreases muscle cell growth and differentiation and increases protein degradation. It is believed that decorin may be involved in anabolic activity in skeletal muscle by inhibiting myostatin. It has been shown that various acute resistance exercises (LL-RE, HL-RE, BFR-RE) result in a systemic release of decorin, and this myokine may be involved in the hypertrophic response to resistance exercise. There appears to be a lack of research investigating the potential role played by myokines in BFR-RE-induced skeletal muscle hypertrophy. The aim of this study is to evaluate the systemic irisin, myostatin and decorin myokines levels after acute BFR-RE and HL-RE, and to measure whether BFR-RE alters the exercise-induced myokine response. We predict that systemic irisin, myostatin and decorin myokine responses to BFR-RE and HL-RE will be similar.

Being tested
BFR-RE, HL-RE
Keywords
blood flow restriction, myokines
Medical subject headings
Muscular Atrophy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BFR-REOther

    In the BFR-RE intervention, the exercise will be done as a set of 30 repetitions with a loading of 30% of 1 RM and an additional 3 sets x 15 repetitions, with 30 seconds rest between sets. In both groups, bilateral leg extension exercise will be performed by using the leg extension machine for resistance exercise. In the blood flow restriction group (BFR-RE), the cuff will be placed in the proximal region of the thigh bilaterally, inflated to a pressure equivalent to 50% of the estimated arterial occlusion pressure (AOP), and leg extension exercise will be performed under this condition. In the BFR-RE group, the blood flow restriction time will be between 5-10 minutes. Venous blood samples will be collected from the arm antecubital region of the participants just before the exercise session, immediately after the exercise, and 1 hour after the exercise. Plasma irisin, myostatin and decorin levels will be measured from the samples taken.

  • HL-REOther

    In the HL-RE intervention, the exercise will be performed with a loading of 80% of 1 RM, with 4 sets x 7 repetitions, with 60 seconds of rest between sets. In both groups, bilateral leg extension exercise will be performed by using the leg extension machine for resistance exercise. Venous blood samples will be collected from the arm antecubital region of the participants just before the exercise session, immediately after the exercise, and 1 hour after the exercise. Plasma irisin, myostatin and decorin levels will be measured from the samples taken.

Study groups in NCT05573321
Study groupRoleWhat they receive
BFR-REExperimentalIn the BFR-RE intervention, the exercise will be done as a set of 30 repetitions with a loading of 30% of 1 RM and an additional 3 sets x 15 repetitions, with 30 seconds rest between sets.
Receives: Other: BFR-RE; Other: HL-RE
HL-REActive comparatorIn the HL-RE intervention, the exercise will be performed with a loading of 80% of 1 RM, with 4 sets x 7 repetitions, with 60 seconds of rest between sets.
Receives: Other: BFR-RE; Other: HL-RE

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. change in irisin concentrations

    It was discovered by Bostrom et al in 2012 as a PGC-1α (peroxisome proliferator-activated receptor coactivator 1-alpha)-dependent myokine. It is proteolytically cleaved from the membrane protein FDNC-5 (fibronectin domain containing protein-5) and secreted from skeletal muscle into the circulation in response to exercise. Irisin is a myokine mainly known for its effect on the conversion of white adipose tissue to brown adipose tissue, thereby increasing thermogenesis and energy metabolism. However, there is new evidence to suggest that the iris may have a role in regulating muscle hypertrophy.

    Measured: immediately before the exercise session, immediately after the exercise and 1 hour after the exercise

  2. change in myostatin concentrations

    It is a member of the TGF-ß (transforming growth factor-beta) family and acts as a negative regulator of skeletal muscle growth.

    Measured: immediately before the exercise session, immediately after the exercise and 1 hour after the exercise

  3. change in decorin concentrations

    It has been identified as another myokine that plays a role in muscle hypertrophy. Decorin is thought to be involved in anabolic activity in skeletal muscle by inhibiting myostatin.

    Measured: immediately before the exercise session, immediately after the exercise and 1 hour after the exercise

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Oct 2022
  2. Study start14 Feb 2023 (estimated)
  3. Primary completionApr 2023 (estimated)
  4. Study completionJun 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Crossover
Masking
Triple blind
Who is masked
Participant, Care provider, Outcomes assessor
Enrolment
22 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05573321
Sponsor's protocol ID
22-7T/59
Status last verified
Feb 2023
First submitted
4 Oct 2022
Last updated
14 Feb 2023
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • American College of Sports Medicine. American College of Sports Medicine position stand. Progression models in resistance training for healthy adults. Med Sci Sports Exerc. 2009 Mar;41(3):687-708. doi: 10.1249/MSS.0b013e3181915670.

    PubMed 19204579
  • Takarada Y, Takazawa H, Sato Y, Takebayashi S, Tanaka Y, Ishii N. Effects of resistance exercise combined with moderate vascular occlusion on muscular function in humans. J Appl Physiol (1985). 2000 Jun;88(6):2097-106. doi: 10.1152/jappl.2000.88.6.2097.

    PubMed 10846023
  • Yasuda T, Ogasawara R, Sakamaki M, Bemben MG, Abe T. Relationship between limb and trunk muscle hypertrophy following high-intensity resistance training and blood flow-restricted low-intensity resistance training. Clin Physiol Funct Imaging. 2011 Sep;31(5):347-51. doi: 10.1111/j.1475-097X.2011.01022.x. Epub 2011 Mar 22.

    PubMed 21771252
  • Pope ZK, Willardson JM, Schoenfeld BJ. Exercise and blood flow restriction. J Strength Cond Res. 2013 Oct;27(10):2914-26. doi: 10.1519/JSC.0b013e3182874721.

    PubMed 23364292
  • Wilk M, Krzysztofik M, Gepfert M, Poprzecki S, Golas A, Maszczyk A. Technical and Training Related Aspects of Resistance Training Using Blood Flow Restriction in Competitive Sport - A Review. J Hum Kinet. 2018 Dec 31;65:249-260. doi: 10.2478/hukin-2018-0101. eCollection 2018 Dec.

    PubMed 30687436
  • Scott BR, Loenneke JP, Slattery KM, Dascombe BJ. Exercise with blood flow restriction: an updated evidence-based approach for enhanced muscular development. Sports Med. 2015 Mar;45(3):313-25. doi: 10.1007/s40279-014-0288-1.

    PubMed 25430600
  • Martin-Hernandez J, Marin PJ, Menendez H, Ferrero C, Loenneke JP, Herrero AJ. Muscular adaptations after two different volumes of blood flow-restricted training. Scand J Med Sci Sports. 2013 Mar;23(2):e114-20. doi: 10.1111/sms.12036. Epub 2012 Dec 27.

    PubMed 23278841
  • Slysz J, Stultz J, Burr JF. The efficacy of blood flow restricted exercise: A systematic review & meta-analysis. J Sci Med Sport. 2016 Aug;19(8):669-75. doi: 10.1016/j.jsams.2015.09.005. Epub 2015 Sep 28.

    PubMed 26463594
  • Mitchell CJ, Churchward-Venne TA, West DW, Burd NA, Breen L, Baker SK, Phillips SM. Resistance exercise load does not determine training-mediated hypertrophic gains in young men. J Appl Physiol (1985). 2012 Jul;113(1):71-7. doi: 10.1152/japplphysiol.00307.2012. Epub 2012 Apr 19.

    PubMed 22518835
  • Morton RW, Oikawa SY, Wavell CG, Mazara N, McGlory C, Quadrilatero J, Baechler BL, Baker SK, Phillips SM. Neither load nor systemic hormones determine resistance training-mediated hypertrophy or strength gains in resistance-trained young men. J Appl Physiol (1985). 2016 Jul 1;121(1):129-38. doi: 10.1152/japplphysiol.00154.2016. Epub 2016 May 12.

    PubMed 27174923
  • Takarada Y, Tsuruta T, Ishii N. Cooperative effects of exercise and occlusive stimuli on muscular function in low-intensity resistance exercise with moderate vascular occlusion. Jpn J Physiol. 2004 Dec;54(6):585-92. doi: 10.2170/jjphysiol.54.585.

    PubMed 15760491
  • Loenneke JP, Wilson JM, Marin PJ, Zourdos MC, Bemben MG. Low intensity blood flow restriction training: a meta-analysis. Eur J Appl Physiol. 2012 May;112(5):1849-59. doi: 10.1007/s00421-011-2167-x. Epub 2011 Sep 16.

    PubMed 21922259
  • Lixandrao ME, Ugrinowitsch C, Berton R, Vechin FC, Conceicao MS, Damas F, Libardi CA, Roschel H. Magnitude of Muscle Strength and Mass Adaptations Between High-Load Resistance Training Versus Low-Load Resistance Training Associated with Blood-Flow Restriction: A Systematic Review and Meta-Analysis. Sports Med. 2018 Feb;48(2):361-378. doi: 10.1007/s40279-017-0795-y.

    PubMed 29043659
  • Loenneke JP, Fahs CA, Wilson JM, Bemben MG. Blood flow restriction: the metabolite/volume threshold theory. Med Hypotheses. 2011 Nov;77(5):748-52. doi: 10.1016/j.mehy.2011.07.029. Epub 2011 Aug 12.

    PubMed 21840132
  • Moritani T, Sherman WM, Shibata M, Matsumoto T, Shinohara M. Oxygen availability and motor unit activity in humans. Eur J Appl Physiol Occup Physiol. 1992;64(6):552-6. doi: 10.1007/BF00843767.

    PubMed 1618195

Questions about this trial

What is this clinical trial studying?

A study testing BFR-RE and HL-RE in people with Muscle Hypotrophy, run by Ege University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 14 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Goksu Gokce (+905378191501, gksgokce@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

change in irisin concentrations (time frame: immediately before the exercise session, immediately after the exercise and 1 hour after the exercise). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05573321, which also lists 37 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Feb 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in